Publication: ONdrug Delivery 180, 26th November 2025

Abstract: With the increasing demand for new inhalation therapies, the need for efficient, patient-centric and sustainable delivery platforms is paramount. The Resyca PFSI is uniquely positioned to meet these needs, enabling precise and reliable delivery of even the most fragile molecules.

Soft Mist Inhaler (SMI) technology is transforming inhaled drug delivery — making treatments more efficient, patient-friendly, and sustainable.

Key highlights from the article:

• Enhanced Usability: SMIs reduce coordination errors and improve lung deposition, supporting better outcomes for diverse patient groups.
• Compatibility with Biologics: Ideal for next-generation therapies like vaccines and gene therapies, where gentle aerosolisation is crucial.
• Innovation with PFSI™: Resyca’s Pre-Filled Syringe Inhaler sets new standards for precision dosing, scalability, and patient-centric design. PFSI – Soft Mist Inhaler SMI.

This innovation is paving the way for tailored dosing, improved treatment adherence, and cost-effective delivery—critical for biologics and high-value therapies.

The post Enhancing drug delivery with innovative soft mist inhaler technology first appeared on Resyca.

Event: DDL 2023, 6 – 8 December 2023, Edinburgh, United Kingdom

Abstract: A device screening method is presented which takes aerosol parameters, deposition modelling, and post aerosolisation mRNA integrity data to predict lung deposition of functional mRNA as a percentage of fill dose. In the prediction performed here, the Aerogen Solo, Pari eFlow rapid, and the Resyca Pulmospray™ result in 12%, 2% and 51% lung deposition of functional mRNA, respectively.

The delivery of full-length mRNA is important, as only full-length mRNA results in the translation of the wanted biological active protein. When selecting a drug delivery device for the inhalation of sensitive biologics, such as mRNA formulations, the device specific drug delivery characteristics must be considered.

Based on nebuliser fill volume, large differences in active mRNA delivery efficiently may exist and careful selection of the device is recommended. Particularly for biological compounds that carry high costs, substantial cost savings may be realised when selecting an efficient delivery device. The Resyca Pulmospray™ device is such an efficient device that may provide up to 50% of the filled mRNA to the deep lung intact.

The post A device screening method for predicting delivery of inhaled mRNA via a nebuliser first appeared on Resyca.

Publication: Drug Development & Delivery, Volume 24(7), 2024

Abstract: Worldwide, rising cases of chronic lung conditions, such as asthma, cystic fibrosis, pulmonary arterial hypertension (PAH), and chronic obstructive pulmonary disease (COPD), are driving demand for inhalation drug delivery devices.

As respiratory diseases rise and biologics rapidly expand, the need for advanced, patient-friendly delivery solutions is accelerating. This article explores how Soft Mist Inhaler (SMI) technology is opening new pathways for inhaled and nasal biologics – from improving dosing performance to reducing reliance on needle-based administration.

By reading our article, you’ll discover:

• Why inhalation and nasal delivery are becoming strategic routes for biologics.
• How reformulation into inhaled or nasal formats can extend product life cycles.
• The key challenges of delivering sensitive biologics — and how soft mist technology overcomes them.
• The critical role of industry partnerships in accelerating device innovation and development efficiency.

Download the full article to find out more.

The post How soft mist inhalers support improved biopharma drug delivery first appeared on Resyca.

Publication: International Pharmaceutical Industry, Volume 14(2), 2022

Abstract: The COVID-19 outbreak has provided a number of lessons for the pharmaceutical industry to consider for future pandemics. Could soft mist inhalers (SMIs), and soft mist nasal sprays in particular, hold the key to improved vaccine delivery?

Biologic vaccines are highly sensitive, and conventional nasal devices can compromise formulation integrity or fail to deliver consistent doses. Next-generation soft mist inhalers (SMIs) and soft mist nasal sprays address these challenges through controlled plume dynamics, narrow spray cone angles, and biologic-compatible nozzle designs that enhance deposition in the upper nasal cavity while minimising particle damage.

Built on modular, standardised platforms, these devices also streamline development, reduce customisation needs, and support faster regulatory and commercialisation timelines. As a result, SMIs and soft mist nasal sprays offer a practical, scalable route to unlocking the full potential of nasal vaccines—strengthening global preparedness and enabling more efficient, accessible vaccination strategies for future pandemics.

Find out more in our article.

The post SMIs & Soft Mist Nasal Sprays – A key defence in the fight against the next pandemic? first appeared on Resyca.

Journal: Pharmaceutics, Volume 13 (11), 2021

Abstract: In COVID-19-induced acute respiratory distress syndrome, the lungs are incapable of filling with sufficient air, leading to hypoxemia that results in high mortality among hospitalised patients.

In clinical trials, low-molecular-weight heparin was administered via a specially designed soft-mist inhaler device in an investigator initiated, single-center, open-label, phase-IIb clinical trial. Patients with evidently worse clinical presentations were classed as the “Device Group”; 40 patients were given low-molecular-weight heparin via a soft mist inhaler at a dose of 4000 IU per administration, twice a day.

The Control Group, also made up of 40 patients, received the standard therapy. The predetermined severity of hypoxemia and the peripheral oxygen saturation of patients were measured on the 1st and 10th days of treatment.

The improvement was particularly striking in cases of severe hypoxemia. In the 10-day treatment, low-molecular-weight heparin was shown to significantly improve breathing capability when delivered via a soft-mist inhaler.

The post Early effects of low molecular weight heparin therapy with soft mist inhaler for COVID-19-Induced Hypoxemia: A phase IIb trial first appeared on Resyca.